Why RA Medications Don't Stop the Damage

Start Here

Series: The Rheumatoid Arthritis Articles | Part 2 of 3

Most people with rheumatoid arthritis are told their condition is being managed when their labs improve. What most are not told is that the system used to manage those labs was not designed to stop the underlying damage.

That distinction sounds subtle. In practice it produces a very specific and very common experience: years of appointments, years of medications, labs that trend in the right direction, and a condition that continues to quietly advance. Joints that progress despite controlled markers. New symptoms that arrive in systems that have nothing to do with the joints. The sense that something is still wrong even when the numbers say otherwise.

This article is an explanation of why that happens. Not a criticism of the practitioners involved. The standard treatment model for rheumatoid arthritis is internally coherent. It's just built around a different target than the one that determines whether the condition resolves.

How the Medication Model Is Actually Designed

To understand why current RA medications work the way they do, it helps to understand what information the prescribing model is working from.

When mitochondria sustain damage, they produce specific inflammatory signals depending on where in the mitochondria the damage has occurred. Different locations produce different cytokines. Damage at one part of the electron transport chain drives TNF-alpha and interleukin-6. Damage at the mitochondrial DNA itself drives different inflammatory pathways. The body maps out which room the damage is in, and that room is the one that calls for help.

Rheumatologists look at those signals. They measure the inflammatory markers in the blood, identify which cytokines are elevated, and prescribe the medication that targets the elevated marker. TNF-alpha elevated: prescribe a TNF inhibitor. Interleukin-6 elevated: prescribe an IL-6 blocker. Specific immune pathway active: prescribe a JAK inhibitor. If the first medication doesn't produce sufficient reduction in the marker, a different one is tried. The process repeats until the markers come down.

This model is scientifically consistent within its framework. It just isn't built to resolve the mechanism driving the condition.

The medications are designed to reduce the signal. They're not designed to address the source of the signal. The source, the mitochondrial damage generating the distress signal that the immune system is responding to, continues running regardless of whether the downstream marker has been suppressed.

The medications reduce the inflammatory signal. They don't address the mitochondrial damage generating it. Managed markers and managed disease are not the same thing.

What Improved Lab Markers Actually Mean

C-reactive protein is one of the most commonly tracked markers in rheumatoid arthritis. When it drops after medication, both patient and practitioner understand this as the condition responding to treatment. Clinically, that interpretation is accurate within the treatment model being used.

What CRP elevation actually reflects at the cellular level is more specific than general inflammation. Elevated CRP means that cytochrome one, the entry point for carbohydrate-derived electrons in the mitochondrial electron transport chain, is damaged and leaking. The mitochondria are sending a distress signal because Complex One has sustained structural damage. Interleukin-6, one of the primary drivers of CRP elevation, is produced when that mitochondrial leaking reaches a threshold that triggers immune response.

Medications that reduce interleukin-6 or block TNF-alpha bring the CRP number down. They do this by interrupting the signaling cascade between the damaged mitochondria and the immune response. The mitochondria are still damaged. The leaking is still occurring. The signal has been reduced. The source has not.

Improved markers do not necessarily mean improved biology. They often mean the signal has been reduced, not the source.

This is why patients who have been on effective RA medications for years, with labs that consistently show reduced inflammation, can still experience joint progression. Why the deformity continues even when the CRP is controlled. Why fatigue persists even when the rheumatoid factor is lower. The metric being tracked is not the metric that determines whether the condition advances. It's the metric that reflects the immune system's response to the damage. Reducing the response doesn't stop the damage.

CRP elevation in RA reflects mitochondrial leaking at Complex One, not general inflammation. Medications that reduce CRP suppress the immune signal without addressing the structural damage generating it. This is why lab improvement and disease progression can occur simultaneously.

Why What You Eat Is Actively Affecting the Damage

Rheumatoid arthritis patients have a specific vulnerability in the electron transport chain that most of them are never told about.

The mitochondrial breakdown in RA occurs at the transfer of electrons from NADH to CoQ10 in the complex portion of the electron transport chain. This creates a specific problem with carbohydrate metabolism. When carbohydrates are broken down for energy, the electrons they produce enter the mitochondrial transport chain at Complex One. In RA patients, Complex One is structurally damaged. Feeding electrons into a damaged Complex One doesn't just fail to produce energy efficiently. It actively generates oxidative stress, contributing to further mitochondrial damage every time carbohydrate-derived electrons are forced through a broken entry point.

This is why many RA patients intuitively feel better when they reduce carbohydrates, even without understanding why. Reducing carbohydrate intake reduces the volume of electrons being forced through the damaged pathway. The system has less opportunity to injure itself with each meal. It's the same logic as not running on a broken ankle. The ankle is still broken. But at least it's not being asked to take full load while it is.

Fat-derived electrons, by contrast, enter the transport chain at Complex Two. In most RA patients, Complex Two retains more of its function. This is why shifting toward fat as a fuel source tends to reduce the oxidative burden and sometimes produces meaningful symptom reduction for RA patients, even in cases where other dietary approaches haven't moved the needle. It's not a cure. It's removing one of the inputs that's actively accelerating the damage.

Why Exertion Sometimes Makes Things Worse

One of the more confusing experiences for RA patients is that exertion, exercise, physical activity, the kinds of things that should logically improve health, sometimes produces disproportionate worsening. Fatigue that doesn't correspond to the level of activity. Increased joint inflammation after physical effort that seems mild. Recovery that takes far longer than it should.

The mechanism behind this is the same damaged electron transport chain. When Complex One is damaged, oxygen can no longer be processed efficiently. Instead of fueling energy production as it's designed to, it contributes to oxidative stress. Physical activity increases oxygen demand. In a healthy mitochondrial system, that increased demand is met with increased energy output. In a damaged system, the increased oxygen throughput amplifies the oxidative damage rather than producing proportional energy. The person works harder and feels worse, not because they're weak or deconditioned, but because the machinery designed to convert that effort into energy is structurally unable to do so.

This also explains why the standard advice to exercise for inflammatory conditions produces variable results in RA patients. For some, it genuinely helps. For others, it worsens symptoms in ways that don't make intuitive sense. The difference often comes down to the specific state of the electron transport chain and how much oxidative load the damaged system can handle before it tips into further injury.

Why Additional Diagnoses Appear Over Time

Rheumatoid arthritis patients frequently develop additional conditions over the course of their disease. Thyroid dysfunction. Neurological symptoms. Cardiovascular involvement. Secondary autoimmune diagnoses. The standard framing treats each of these as separate conditions that happen to occur alongside the rheumatoid arthritis.

They're not separate. They're extensions of the same underlying process.

The cellular energy deficit that starts with mitochondrial damage in one tissue doesn't stay contained. As the body's overall redox potential drops, as the proportion of damaged mitochondria increases across different cell types, the energy deficit begins affecting every system that depends on adequate mitochondrial function. The thyroid is particularly vulnerable because sixty percent of thyroid hormone is used by cells to maintain cellular voltage. When the energy system is already compromised, thyroid function follows. The brain, which consumes twenty to twenty-five percent of total cardiac output while producing no energy for the rest of the body, begins experiencing the cognitive effects of an energy system running below capacity.

This is why additional diagnoses often appear over time. Not as separate conditions, but as extensions of the same underlying process reaching new tissues as the energy deficit deepens.

Almost fifty percent of people with one autoimmune diagnosis will develop a second by the time they've been in the system for a while. This statistic is usually presented as coincidence or genetic predisposition. The more accurate explanation is that the mechanism that produced the first condition was never addressed, and it found the next available tissue to express itself in.

Secondary diagnoses in RA patients are rarely coincidental. They're the same energy deficit reaching new tissues as the underlying process continues unaddressed.

What Controlled Actually Means

From the outside, successful RA management can look like progress. Symptoms improve. Labs stabilize. The rheumatology appointment produces reassuring numbers. The condition appears controlled.

Underneath, the process that produced it is still active.

The mitochondrial damage continues accumulating. The heteroplasmy rate, the proportion of damaged mitochondrial DNA in the affected tissues, keeps climbing. The biological clock that tracks cellular aging keeps running faster than it should. And the inflammatory signals that the medications are suppressing keep being generated, because the source that generates them hasn't been reached by anything in the treatment.

This isn't a reason to stop medications that are reducing pain and protecting joint function. It's a reason to understand what those medications are and aren't doing. Managing the outputs of a process and stopping the process itself are different outcomes that require different approaches.

Controlled RA is not the same as resolved RA. Medications suppress the inflammatory signals produced by mitochondrial damage. The damage continues accumulating beneath those suppressed signals. The distinction between managing outputs and addressing the source is where outcomes diverge.

If the goal is to do more than manage the outputs, if the goal is to stop the process itself, then the approach has to change.

Part 3 of this series covers what that change looks like.

Where to Go From Here

If you haven't read Part 1 of this series,

What Rheumatoid Arthritis Is Actually Doing to Your Body covers the mechanism behind RA in full, including the cardiac risk data, the synovial fluid research, and the specific way mitochondrial DNA damage produces the antibody patterns that show up in labs.

Part 3,

What Actually Has to Change for RA to Improve, addresses the evaluation framework and intervention sequence required to reach the mitochondrial damage directly, rather than managing what it produces.

For the broader explanation of why this pattern applies across chronic illness, not just rheumatoid arthritis,

The Real Reason Your Body Isn't Healing (Energetic Debt Explained) and Why We Don't Treat Conditions, We Treat Patterns both cover the foundational framework in depth.

Find Out Whether Your RA Is Controlled or Actually Addressed

There is a difference between suppressed inflammatory markers and a resolved mechanism.

A real assessment shows which one you have.

[ BOOK YOUR CONSULTATION ]

Dr. Rob DeMartino D.C. | Energetic Debt Method

This article is educational and does not constitute individual medical advice. Outcomes vary by patient and condition.

Frequently Asked Questions

These questions reflect what patients commonly search when they're trying to understand why their RA continues to progress despite medication and what controlled disease actually means.

Why does my rheumatoid arthritis keep progressing even though my labs are improving?

Lab markers in RA, including CRP and rheumatoid factor, reflect the immune system's response to mitochondrial damage rather than the damage itself. Medications that reduce those markers suppress the signaling cascade between the damaged mitochondria and the immune response. The mitochondrial damage continues accumulating beneath the suppressed signals. This is why patients with well-controlled labs can still experience joint progression, fatigue, and the development of secondary conditions. The metric being managed is not the metric that determines whether the underlying process advances.

What does it mean that improved lab markers don't mean improved biology?

In rheumatoid arthritis, the inflammatory markers that medications target, TNF-alpha, interleukin-6, CRP, are downstream outputs of mitochondrial damage. They reflect what the immune system is doing in response to a signal from damaged cells. Reducing those markers is clinically meaningful because it reduces pain, protects joint function, and improves quality of life. It doesn't stop the mitochondrial damage generating the signal in the first place. Improved biology would mean the source of the signal is being addressed. Improved markers mean the response to the signal has been reduced. Both are real outcomes. Only one of them reaches the mechanism.

Why do rheumatoid arthritis doctors try different medications if one doesn't work?

Different medications target different cytokines. Which cytokine is most elevated depends on which part of the mitochondria sustained damage, because different damage locations produce different inflammatory signals. Rheumatologists measure the markers, identify which cytokine pathway is most active, and prescribe the medication matched to that pathway. If the first medication doesn't produce sufficient reduction, another is tried. This approach is scientifically logical within a model designed to manage inflammatory outputs. It doesn't address the question of why the mitochondria are producing those signals or how to stop the damage from continuing.

Why do RA patients often feel worse with exercise even though exercise is supposed to help inflammation?

In rheumatoid arthritis, Complex One of the mitochondrial electron transport chain is structurally damaged. Physical activity increases oxygen demand throughout the body. In a healthy mitochondrial system, increased oxygen demand produces proportionally more energy. In a damaged system, increased oxygen throughput amplifies oxidative stress because the machinery designed to process that oxygen efficiently isn't functioning correctly. This is why some RA patients experience disproportionate fatigue, increased joint inflammation, and prolonged recovery after activity that seems mild. The level of effort isn't the problem. The machinery being asked to handle it is.

Why do RA patients sometimes feel better when they reduce carbohydrates?

Carbohydrate-derived electrons enter the mitochondrial electron transport chain at Complex One, which is the specific location damaged in rheumatoid arthritis. Forcing electrons through a structurally damaged entry point generates oxidative stress and contributes to further mitochondrial damage with each meal that relies heavily on carbohydrates. Reducing carbohydrate intake reduces the volume of electrons being sent through the damaged pathway, which reduces the ongoing oxidative injury. Fat-derived electrons enter at Complex Two, which retains more function in most RA patients, making fat a cleaner fuel source for a system with Complex One damage.

Why do so many RA patients eventually develop additional autoimmune conditions?

The cellular energy deficit that produces rheumatoid arthritis doesn't stay confined to joint tissue. As the proportion of damaged mitochondria increases across the body over time, the energy deficit begins affecting every system that depends on adequate mitochondrial function. The thyroid, the nervous system, the cardiovascular system, and other immune-regulated tissues are all vulnerable. Nearly half of people with one autoimmune diagnosis will develop a second over time. This statistic reflects not coincidence or separate genetic events, but the same underlying mechanism reaching new tissues as the energy deficit deepens and the source continues unaddressed.

What is the difference between managed RA and resolved RA?

Managed RA means the inflammatory signals produced by mitochondrial damage have been suppressed to a level where symptoms are reduced and joint damage is slowed. The mitochondrial damage continues accumulating. The heteroplasmy rate, meaning the proportion of damaged mitochondrial DNA in affected tissues, keeps increasing. Biological aging accelerates faster than it should. Resolved RA, in the sense of the underlying mechanism being addressed, would require the mitochondrial damage to be assessed and the energy system producing it to be restored. That requires a different evaluation and a different intervention model than the one designed to manage inflammatory outputs.

Should I stop taking my RA medications if they're not fixing the underlying problem?

This article is not suggesting that. RA medications reduce pain, protect joint function, and improve daily quality of life for many patients. What it's describing is the distinction between what those medications do and what they don't do. Managing inflammatory outputs is clinically real and valuable. It just doesn't reach the mechanism that determines whether the condition advances at the cellular level. Understanding that distinction helps patients ask better questions about what their current treatment is producing and what a different kind of evaluation might reveal. Part 3 of this series covers what addressing the mechanism, rather than its outputs, actually involves.

Conventional medical care vs. Superior Health Solutions natural healthcare

Related video